The First-in-human Study of SRN-001 in Healthy Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 8, 2023

Primary Completion Date

March 15, 2024

Study Completion Date

September 25, 2024

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG

SRN-001

siRNA therapeutics, Self Assembled Micelle inhibitory RNA platform utilized

DRUG

Placebo

0.9% Sodium Chloride(Normal saline)

Trial Locations (1)

CMAX Clinical Research, Adelaide

All Listed Sponsors

lead

siRNAgen Therapeutics Inc.

INDUSTRY

NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants | Biotech Hunter | Biotech Hunter